STATEMENT OF USE - TO EXAMINER
to examiner
on 22 Oct 2024
Last Applicant/ Owned by
Galileilaan 19
Niel
BE
2845
Serial Number
97728325 filed on 22nd Dec 2022
Registration Number
N/A
Correspondent Address
Cheryl L. Burbach
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
ETHERNA
Scientific research and development; pharmaceutical research and development services; medical research and development services; scientific, pharmaceutical, and medical research and development in the field of mRNA therapeutics; scientific, pharmaceutical, and medical research and development in the field of proprietary lipids and lipid nanoparticle formulations for the delivery of mRNA therapeut Read More
Classification Information
Class [042]
Computer & Software Services & Scientific Services
Scientific research and development; pharmaceutical research and development services; medical research and development services; scientific, pharmaceutical, and medical research and development in the field of mRNA therapeutics; scientific, pharmaceutical, and medical research and development in the field of proprietary lipids and lipid nanoparticle formulations for the delivery of mRNA therapeutics for the treatment of various medical disorders, cancer, and infectious diseases
First Use Date in General
30th Oct 2013
First Use Date in Commerce
30th Oct 2013
Class [005]
Pharmaceutical Products
Vaccines; vaccine adjuvants; medical, biological, and pharmaceutical preparations for medical use, namely, preparations containing messenger RNA for preventing and treating viruses, medical disorders, and diseases, namely, viral infections, bacterial infections, cancer, viral, bacterial, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; mRNA-based therapeutics and therapeutic agents for in prevention and treatment of viruses, medical disorders, and diseases, namely, viral infections, bacterial infections, cancer, viral, bacterial, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; lipid nanoparticles for pharmaceutical, medical or diagnostic purposes for preventing and treating viruses, medical disorders, and diseases, namely, viral infections, bacterial infections, cancer, viral, bacterial, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; drug carriers for medical use, namely, drug delivery agents consisting of lipid nanoparticles that facilitate delivery of a wide range of pharmaceuticals; lipid nanoparticles for drug delivery sold as an integral component of drugs in the nature of pharmaceutical preparations for preventing and treating viruses, medical disorders, and diseases, viral infections, bacterial infections, cancer, viral, bacterial, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; pharmaceutical preparations, namely, messenger RNA and delivery agents comprised of lipid nanoparticle carriers and polymers for the delivery of mRNA to human cells for preventing and treating viruses, medical disorders, and diseases, namely, viral infections, bacterial infections, cancer, viral, bacterial, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders
First Use Date in General
30th Oct 2013
First Use Date in Commerce
30th Oct 2013
Class [001]
Chemical Products
Biological preparations for scientific and research purposes for boosting cells in the immune system for improved therapies; biological preparations for scientific and research purposes, namely, a mRNA-based composition for enhancing immunities; biological preparations in the nature of genetically modified cells and vectors for scientific and research purposes; biological and chemical reagents including complexes of these molecules for research purposes, for clinical research, clinical chemistry, clinical trials, scientific research, medical research, laboratory research, and for industrial use, namely, for use in the manufacture of pharmaceuticals
First Use Date in General
30th Oct 2013
First Use Date in Commerce
30th Oct 2013
Class [040]
Treatment & Processing of Materials Services
Custom manufacture of pharmaceutical and medical preparations; custom manufacture of mRNA molecules; custom manufacture of mRNA molecules formulated in lipid nanoparticles; custom manufacture of mRNA for use in vaccines, cell therapy, gene editing, protein replacement, and antibodies; provision of information, advice and consultancy services relating to all of the aforesaid
First Use Date in General
30th Oct 2013
First Use Date in Commerce
30th Oct 2013
Mark Details
Serial Number
No 97728325
Mark Type
No Service Mark
Attorney Docket Number
No 58294/4658
44D Filed
No
44D Current
No
44E filed
No
44E Current
No
66A Filed
No
66A Current
No
Current Basis
No
No Basis
No
Legal History
| Status Date | Action Taken |
|---|---|
| 22nd Oct 2024 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| 22nd Oct 2024 | STATEMENT OF USE PROCESSING COMPLETE |
| 16th Aug 2024 | TEAS STATEMENT OF USE RECEIVED |
| 16th Aug 2024 | USE AMENDMENT FILED |
| 13th Aug 2024 | SOU EXTENSION 1 GRANTED |
| 13th Aug 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| 13th Aug 2024 | SOU TEAS EXTENSION RECEIVED |
| 13th Aug 2024 | SOU EXTENSION 1 FILED |
| 27th Feb 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| 02th Jan 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |